Quiz: Evolving Treatment Options in BRAF V600E Mutant Metastatic Colorectal Cancer
In our gastrointestinal cancer quiz, you’ll get a chance to test your knowledge on the BRAF V600E mutation in patients with colorectal cancer.
In our gastrointestinal cancer quiz, you’ll get a chance to test your knowledge on the BRAF V600E mutation in patients with colorectal cancer. Here’s your first question:
1. What combination treatment was studied in the BEACON CRC study of patients with BRAF V600E mutated metastatic colorectal cancer?
A. Encorafenib (Braftovi), cetuximab (Erbitux), and binimetinib (Mektovi)
B. Vemurafenib (Zelboraf), dabrafenib, and trametinib
C. Dabrafenib, cetuximab, and encorafenib
D. Vemurafenib, trametinib, and binimetinib
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
FDA Issues CRL for Zolbetuximab in Advanced CLDN18.2+ Gastric Cancer
January 9th 2024The FDA cannot approve the application for zolbetuximab in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma due to unresolved issues following a pre-license inspection of a third-party manufacturing site.
Quiz: Detecting Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma
August 10th 2020In our liver cancer quiz, you’ll get a chance to test your knowledge on recurrence following resection in patients with intrahepatic cholangiocarcinoma and the new tools being developed to aid in treating this patient population.
